Myriad Genetics (NASDAQ:MYGN) Cut to “Market Perform” at Leerink Partners
Myriad Genetics (NASDAQ:MYGN – Get Free Report) was downgraded by research analysts at Leerink Partners from an “outperform” rating to a “market perform” rating in a note issued to investors on Monday, MarketBeat reports. They currently have a $21.00 target price on the stock, down from their prior target price of $30.00. Leerink Partners’ price […]
More Stories
US Accuses China of ‘Industrial-Scale’ AI Theft Ahead of Trump’s Visit
By Michael Zhuang The White House has issued a sharply worded memo accusing China-linked entities of systematically stealing U.S. artificial...
CDC Investigating Multi-State Salmonella Outbreak Linked to Backyard Poultry
By Jack Phillips The Centers for Disease Control and Prevention has said it is investigating an outbreak of salmonella bacterial...
US Allows Venezuela to Fund Maduro’s Defense After Court Challenge
By Tom Gantert The United States will ease sanctions on Venezuela to allow its regime to pay legal fees for...
Monsanto Weedkiller Case Could Upend Billions in Compensation
By Troy Myers and Jacob Burg Like countless homeowners, John Durnell of Missouri used a popular herbicide to keep his...
Planned Obsolescence: The Silent Sabotage of the Devices We Depend On
By Stephen Zogopoulos, USNN World News The Illusion of Progress Walk into any electronics store today and you’ll see the...
Shots Fired at White House Correspondents’ Dinner, Trump Evacuated, Suspect Detained
By Emel Akan and Sam Dorman President Donald Trump and First Lady Melania Trump were evacuated from the White House...